信迪利单抗联合紫杉醇、奈达铂治疗晚期非小细胞肺癌的效果观察  

To Observe the Effect of Sintilimab Combined with Paclitaxel and Nedaplatin in the Treatment of Advanced Non-small Cell Lung Cancer

作　　者：宋和平[1] 陈嘉捷 SONG Heping;CHEN Jiajie(Pingdingshan First People's Hospital(Pingdingshan College First Affiliated Hospital),Pingdingshan,467000)

机构地区：[1]河南省平顶山市第一人民医院,平顶山学院第一附属医院,467000

出　　处：《实用癌症杂志》2025年第2期227-229,共3页The Practical Journal of Cancer

摘　　要：目的 观察信迪利单抗联合紫杉醇、奈达铂治疗晚期非小细胞肺癌的疗效及安全性。方法 选取非小细胞肺癌晚期患者120例,简单随机法分为对照组(n=60)和观察组(n=60),对照组予以奈达铂(80 mg/m^(2))+紫杉醇(260 mg/m^(2))治疗,观察组予以奈达铂(80 mg/m^(2))+紫杉醇(260 mg/m^(2))+信迪利单抗(200 mg/m^(2))治疗,记录2组临床疗效、血清肿瘤标志物、免疫细胞水平、不良反应。结果 观察组ORR高于对照组(P<0.05)。观察组治疗后CEA、SCCA水平、Th1/Th2、Th17/Treg水平均低于对照组(P<0.05),CD4+/CD8+水平高于对照组(P<0.05)。2组不良反应比较,差异无统计学意义(P>0.05)。结论 信迪利单抗联合紫杉醇、奈达铂治疗晚期非小细胞肺癌,可有效提高疗效,其治疗作用可能与调节肿瘤标志物水平、免疫细胞水平有关,且不良反应可控。Objective To observe the efficacy and safety of sintilimab combined with paclitaxel and nedaplatin in the treatment of advanced non-small cell lung cancer.Methods A total of 120 patients with advanced non-small cell lung cancer were selected and randomly divided into the control group(n=60)and the observation group(n=60).The control group was treated with nedaplatin(80 mg/m^(2))and paclitaxel(260 mg/m^(2)).The observation group was treated with nedaplatin(80 mg/m^(2))+paclitaxel(260 mg/m^(2))+sintilimab(200 mg/m^(2)).The clinical efficacy,serum tumor markers,immune cell levels,and adverse reactions of the 2 groups were recorded.Results The ORR of the observation group was higher than that of the control group(P<0.05).After treatment,the levels of CEA,SCCA,Th1/Th2 and Th17/Treg in the observation group were lower than those in the control group(P<0.05),and the level of CD4+/CD8+was higher than that in the control group(P<0.05).There was no significant difference in adverse reactions between the 2 groups(P>0.05).Conclusion Sintilimab combined with paclitaxel and nedaplatin can effectively improve the efficacy of patients with advanced non-small cell lung cancer.Its therapeutic effect may be related to the regulation of tumor markers and immune cell levels,and the adverse reactions are controllable.

关 键 词：非小细胞肺癌 晚期 信迪利单抗 紫杉醇 奈达铂 

分 类 号：R734.2[医药卫生—肿瘤]